Infusion of adipose‑derived mesenchymal stem cells inhibits skeletal muscle mitsugumin 53 elevation and thereby alleviates insulin resistance in type 2 diabetic rats

Deng,Zihui; Xu,Huiyan; Zhang,Jinying; Yang,Chen; Jin,Liyuan; Liu,Jiejie; Song,Haijing; Chen,Guanghui; Han,Weidong; Si,Yiling

doi:10.3892/mmr.2018.8901

Infusion of adipose‑derived mesenchymal stem cells inhibits skeletal muscle mitsugumin 53 elevation and thereby alleviates insulin resistance in type 2 diabetic rats

Authors:
- Zihui Deng
- Huiyan Xu
- Jinying Zhang
- Chen Yang
- Liyuan Jin
- Jiejie Liu
- Haijing Song
- Guanghui Chen
- Weidong Han
- Yiling Si
View Affiliations

Affiliations: Institute of Basic Medicine Science, Chinese PLA General Hospital, Beijing 100853, P.R. China, Department of Traditional Chinese Medicine, Chinese PLA General Hospital, Beijing 100853, P.R. China, Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, P.R. China
Published online on: April 19, 2018 https://doi.org/10.3892/mmr.2018.8901
Pages: 8466-8474

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It is widely accepted that infusion of mesenchymal stem cells (MSCs) ameliorates hyperglycemia by alleviating insulin resistance in rats with type 2 diabetes mellitus (T2D). However, the detailed underlying mechanisms are not clearly defined. Mitsugumin 53 (MG53) is an E3 ligase that has recently been implicated in the aggravation of insulin resistance by promoting the ubiquitinoylation of insulin receptor substrate‑1 (IRS‑1) in skeletal muscles. It was therefore hypothesized that MG53 may be involved in MSC‑mediated therapeutic effects on insulin resistance. To test this hypothesis, in the present study, T2D rat models were induced by a high‑fat diet combined with streptozotocin administration and MSC infusion was performed four times (once every 2 weeks for 8 weeks). The therapeutic effects of MSC infusion on insulin resistance were evaluated and the effect on the expression of MG53 and insulin receptor signaling elements in skeletal muscle was also investigated by immunofluorescence staining and western blotting. The results demonstrated that MSC infusion ameliorated hyperglycemia and insulin resistance in T2D rats. Furthermore, MSC infusion inhibited MG53 elevation and reversed the decreases in glucose transporter type 4, insulin receptor, IRS‑1 and phosphorylated‑AKT levels in the skeletal muscle of T2D rats. These results indicated that MSC infusion has therapeutic effects in rats and that MG53 in skeletal muscle may be a promising novel therapeutic target protein for MSC‑mediated amelioration of insulin resistance in T2D.

View Figures

View References

1	Chen L, Magliano DJ and Zimmet PZ: The world wide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rew Endocrinol. 8:228–236. 2011. View Article : Google Scholar
2	Shaw JE, Sicree RA and Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 87:4–14. 2010. View Article : Google Scholar : PubMed/NCBI
3	Fonseca VA: Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 32 Suppl 2:S151–S156. 2009. View Article : Google Scholar : PubMed/NCBI
4	Stumvoll M, Goldstein BJ and van Haeften TW: Type 2 diabetes: Principles of pathogenesis and therapy. Lancet. 365:1333–1346. 2005. View Article : Google Scholar : PubMed/NCBI
5	Russell ND and Cooper ME: 50 years forward: Mechanisms of hyperglycemia driven diabetic complications. Diabetologia. 58:1708–1714. 2015. View Article : Google Scholar : PubMed/NCBI
6	Wang ZV and Hill JA: Diabetic cardiomyopathy: Catabolism driving metabolism. Circulation. 131:771–773. 2015. View Article : Google Scholar : PubMed/NCBI
7	Shi Y and Vanhoutte PM: Macro- and microvascular endothelial dysfunction in diabetes. J Diaberes. 9:434–449. 2017. View Article : Google Scholar
8	Shih KC, Lam KS and Tong L: A systematic review on the impact of diabetes mellitus on the ocular surface. Nutr Diabetes. 7:e2512017. View Article : Google Scholar : PubMed/NCBI
9	Lim AKh: Diabetic nephropathy-complications and treatment. Int J Nephrol Renovasc Dis. 7:361–381. 2014. View Article : Google Scholar : PubMed/NCBI
10	Volmer-Thole M and Lobmann R: Neuropathy and diabetic foot syndrome. Int J Mol Sci. 17:pii: E917. 2016. View Article : Google Scholar : PubMed/NCBI
11	Lilly MA, Davis MF, Fabie JE, Terhune EB and Gallicano GI: Current stem cell based therapies in diabetes. Am J Stem Cells. 5:87–98. 2016.PubMed/NCBI
12	Liu X, Wang Y, Li Y and Pei X: Research status and prospect of stem cells in the treatment of diabetes mellitus. Sci China Life Sci. 56:306–312. 2013. View Article : Google Scholar : PubMed/NCBI
13	Orbay H, Tobita M and Mizuno H: Mesenchymal stem cells isolated from adipose and other tissues: Basic biological properties and clinical applications. Stem Cells Int. 2012:4617182012. View Article : Google Scholar : PubMed/NCBI
14	Cao M, Pan Q, Dong H, Yuan X, Li Y, Sun Z, Dong X and Wang H: Adipose-derived mesenchymal stem cells improve glucose homeostasis in hight-fat diet-induced obese mice. Stem Cell Res The. 6:2082015. View Article : Google Scholar
15	Hao H, Liu J, Shen J, Zhao Y, Liu H, Hou Q, Tong C, Ti D, Dong L, Cheng Y, et al: Multiple intravenous infusion of bone marrow mesenchymal stem cells reverse hyperglycemia in experimental type 2 diabetes rats. Biochem Biophys Res Commun. 436:418–423. 2013. View Article : Google Scholar : PubMed/NCBI
16	Aali E, Mirzamohammadi S, Ghaznavi H, Madjd Z, Larijani B, Rayegan S and Sharifi AM: A comparative study of mesenchymal stem cell transplantation with its paracrine effect on control of hyperglycemia in type 1 diabetic rats. J Diabetes Metab Disord. 13:762014. View Article : Google Scholar : PubMed/NCBI
17	Xie M, Hao HJ, Cheng Y, Xie ZY, Yin YQ, Zhang Q, Gao JQ, Liu HY, Mu YM and Han WD: Adipose-derived mesenchymal cells ameliorate hyperglycemia through regulating hepatic glucose metabolism in type 2 diabetic rats. Biochem Biophys Res Commun. 483:435–441. 2017. View Article : Google Scholar : PubMed/NCBI
18	Cheng SK, Park EY, Pehar A, Rooney AC and Gallicano GI: Current progress of human trials using stem cell therapy as a treatment for diabetes mellitus. Am J Stem Cells. 5:74–86. 2016.PubMed/NCBI
19	Si Y, Zhao Y, Hao H, Liu J, Guo Y, Mu Y, Shen J, Cheng Y, Fu X and Han W: Infusion of mesenchymal stem cells ameliorates hyperglycemia in type 2 diabetes rats: Identification of a novel role in improving insulin sensitivity. Diabetes. 61:1616–1625. 2012. View Article : Google Scholar : PubMed/NCBI
20	Pde Bueno G, Yochite JN, Derigge-Pisani GF, de Farias Malmegrim KC, de Avó LR, Voltarelli JC and Leal ÂM: Metabolic and pancreatic effects of bone marrow mesenchymal stem cells transplantation in mice fed high-fat diet. PLoS One. 10:e01243692015. View Article : Google Scholar : PubMed/NCBI
21	Hughey CC, Ma L, James FD, Bracy DP, Wang Z, Wasserman DH, Rottman JN, Hittel DS and Shearer J: Mesenchymal stem cell transplantation for the infracted heart: Therapeutic potential for insulin resistance beyond the heart. Cardiovasc Diabetol. 12:1282013. View Article : Google Scholar : PubMed/NCBI
22	Shree N and Bhonde RR: Conditioned media from adipose tissue derived mesenchymal stem cells reverse insulin resistance in cellular models. J Cell Biochem. 118:2037–2043. 2017. View Article : Google Scholar : PubMed/NCBI
23	Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA and Shulman RG: Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med. 322:223–228. 1990. View Article : Google Scholar : PubMed/NCBI
24	Song R, Peng W, Zhang Y, Lv F, Wu HK, Guo J, Cao Y, Pi Y, Zhang X, Jin L, et al: Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature. 494:375–379. 2013. View Article : Google Scholar : PubMed/NCBI
25	Yi JS, Park JS, Ham YM, Nguyen N, Lee NR, Hong J, Kim BW, Lee H, Lee CS, Jeong BC, et al: MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signaling. Nat Commun. 4:23542013. View Article : Google Scholar : PubMed/NCBI
26	Ma H, Liu J, Bian Z, Cui Y, Zhou X, Zhou X, Zhang B, Adesanya TM, Yi F, Park KH, et al: Effects of metabolic syndrome on mitsugumin 53 expression and function. PLoS One. 10:e01241282015. View Article : Google Scholar : PubMed/NCBI
27	Lee H, Park JJ, Nguyen N, Park JS, Hong J, Kim SH, Song WY, Kim HJ, Choi K, Cho S, et al: MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction disruptor sensitizes insulin signaling in skeletal muscle. J Biol Chem. 291:26627–26635. 2016. View Article : Google Scholar : PubMed/NCBI
28	Cai C, Masumiya H, Weisleder N, Matsuda N, Nishi M, Hwang M, Ko JK, Lin P, Thornton A, Zhao X, et al: MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol. 11:56–64. 2009. View Article : Google Scholar : PubMed/NCBI
29	Tan T, Ko YG and Ma J: Dual function of MG53 in membrane repair and insulin signaling. BMB Rep. 49:414–423. 2016. View Article : Google Scholar : PubMed/NCBI
30	Yang C, Deng ZH, Chen S, Chen S, Zhang JY, Jin LY, Si YL and Chen GH: Adipose-derived mesenchymal stem cells alleviating heart dysfunction through suppressing MG53 protein in rat model of diabetic cardiomyopathy. Int J Clin Exp Pathol. 10:4009–4022. 2017.
31	Rea S and James DE: Moving GLUT4: The biogenesis and trafficking of GLUT4 storage vesicles. Diabetes. 46:1667–1677. 1997. View Article : Google Scholar : PubMed/NCBI
32	Sylow L, Kleinert M, Pehmøller C, Prats C, Chiu TT, Klip A, Richter EA and Jensen TE: Akt and Rac1 signaling are jointly required for insulin-stimulated glucose uptake in skeletal muscle and downregulated in insulin resistance. Cell Signal. 26:323–331. 2014. View Article : Google Scholar : PubMed/NCBI
33	Xie Z, Hao H, Tong C, Cheng Y, Liu J, Pang Y, Si Y, Guo Y, Zang L, Mu Y and Han W: Human umbilical cord-derived mesenchymal stem cells elicit macrophages into an anti-inflammatory phenotype to alleviate insulin resistance in type 2 diabetic rats. Stem Cells. 34:627–639. 2016. View Article : Google Scholar : PubMed/NCBI
34	Laustsen PG, Michael MD, Crute BE, Cohen SE, Ueki K, Kulkarni RN, Keller SR, Lienhard GE and Kahn CR: Lipoatrophic diabetes in Irs1(−/−)/Irs3(−/−) double knockout mice. Genes Dev. 16:3213–3222. 2002. View Article : Google Scholar : PubMed/NCBI
35	Bunner AE, Chandrasekera PC and Barnard ND: Knockout mouse models of insulin signaling: Relevance past and future. Word J Diabetes. 5:146–159. 2014. View Article : Google Scholar